The effect of SIM5 on bone marrow-derived mononuclear cells of multiple myeloma patients

Abstract

Background and Objective: Cancers are among the serious problems in communities. In recent years, herbal products have been very promising regarding their anti-tumor and immunomodulatin potentials. SIM5, a herbal preparation, has had good results in discriminating between cancerous cell lines and normal cells, but have not examined directly on patients cells yet. In this study, bone marrow mononuclear cells from cancerous and non-cancerous samples were used to study the effects of SIM5.


Materials and Methods: Remained bone marrow samples of multiple myeloma patients (7 cases) and individuals who clinically needed bone marrow examination, but finally were diagnosed with no serious pathologic conditions in their leukocytes (7 cases) were considered as control group. Mononuclear cells were isolated and cultured with SIM5 and R10 fraction. After 48 h incubation, toxicity was assessed using LDH release test and vital activity with MTT test.


Results: Cell toxicity with SIM5 was observed only in multiple myeloma samples and not in control group samples. There was a strong correlation between toxicity and the number of plasma cells in bone marrow mononuclear cells. SIM5 induced a decrease in vital activity of cancerous cells but an increase in the normal bone marrow samples.


Conclusion: SIM5 has distinct effects on normal and cancerous cells, and its toxic effect is focused on the latter. Therefore, it possesses the properties of an ideal product to be studied more seriously.

Keywords

References

1. Urruticoechea A, Alemany R, Balart J, Villanueva A, Vinals F, Capella G. (2010) Recent advances in cancer therapy: an overview. Current Pharmaceutical Design. 16(1): 3-10. 2. Heider U, Fleissner C, Zavrski I, Kaiser M, Hecht M, Jakob C, Sezer O. Bone markers in multiple myeloma. European Journal of Cancer. 2006; 42(11): 1544-53. 3. Silvestris F, Lombardi L, De Matteo M, Bruno A, Dammacco F. Myeloma bone disease: pathogenetic mechanisms and clinical assessment. Leukocyte Research. 2007; 31(2): 129-38. 4. Armirage JO, Longo DL. Harrison's principles of internal medicine. 16th ed. USA. McGraw-Hill componies,Inc. 2005: 641-655. 5. Bierman J, Harris N, Armitage JO. Cecil textbook of medicine. 22nd ed. California. Elsevir Inc. 2004: 1174-1183. 6. Nooka A, Lonial S. Sequential or combination therapy for multiple myeloma. Expert Reviews in Hematology. 2012; 5(5): 533-45. 7. Slavin S, Morecki S, Weiss L, Or R. Immunotherapy of hematologic malignancies and metastatic solid tumors in experimental animals and man. Critcal Reviews in Oncology/Hematology. 2003; 46(2): 139-63. 8. Ruan WJ, Lai MD, Zhou JG. Anticancer effects of chines herbal medicine, science or myth. Journal of Zhejiang University Science. 2006; 7(12): 1006-14. 9. Ranga RS. A herbal medicine for treatment of lung cancer. Molecular Cell 2005; 280 (1-2): 125-33. 10. Yaraee R, Ghazanfari T, Shams JAD, Esmaeili M. Jamali D. The Eeffect of herbal extract SIM5 on lymphoma cell lines and blood mononuclear cells. Daneshvar Medicine 2008; 15(73): 73-78. 11. Yaraee R, Kamalinejad M, Ghazanfari T, Eghtedardoost M. Discriminative Effect of SIM5 and its fractions on normal and cancerous lymphocytes. The 17th national & 5th International Conference of Biology of Iran. 2012. 12. Burton JD. The MTT assay to evaluate chemosensitivity. Methods in Molecular Medicine. 2005; 110: 69-78. 13. Morgan DML. Tetrazolium (MTT) Assay for Cellular Viability and Activity. Methods in Molecular Medicine. 1998; 79: 179-83. 14. Yaraee R. , Kamalinejad M., Rajabian T. Eghtedardoost, M , Jamali D. Comparison of toxic effects of SIM5 and its fractions on normal resting, activated and cancerous cells. daneshvarmed. 2016; 24(125):1-12. 15. Kawano Y, Moschetta M, Manier S, Glavey S, Görgün GT, Roccaro AM, Anderson KC, Ghobrial IM. Targeting the bone marrow microenvironment in multiple myeloma. Immunological Reviews. 2015 Jan; 263(1): 160-72. 16. Rebersek K, Cernelc P, Podgornik H. Evaluation of multiple myeloma cell apoptosis in primary bone marrow samples. Clinical laboratory. 2013; 59(3-4): 389-95.
Daneshvar Medicine
Volume 24, Issue 5 - Serial Number 126
November and December 2016
Pages 25-34

Files

Share

How to cite

Statistics